12:00 AM
 | 
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Contrave: SPA received

Orexigen said it reached an agreement with FDA on an SPA for the cardiovascular outcomes trial of obesity product Contrave that the agency requested in a complete response letter last year (see BioCentury, Feb. 7, 2011). The trial, expected to begin in late 2Q12, will enroll about 10,000 patients. An interim...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >